Leerink Partners initiated coverage on Lexeo Therapeutics with a new price target

11/28/23 7:29:00 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Leerink Partners initiated coverage of Lexeo Therapeutics with a rating of Outperform and set a new price target of $19.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LXEO

Date	Price Target	Rating	Analyst
6/13/2024	$28.00	Outperform	Robert W. Baird
6/6/2024	$22.00	Buy	H.C. Wainwright
11/28/2023	$20.00	Overweight	JP Morgan
11/28/2023	$20.00	Buy	Stifel
11/28/2023	$19.00	Outperform	Leerink Partners
11/28/2023	$22.00	Outperform	RBC Capital Mkts
11/28/2023	$23.00	Buy	Chardan Capital Markets